18669454

Source:http://linkedlifedata.com/resource/pubmed/id/18669454

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0034380, umls-concept:C0034656, umls-concept:C0045093, umls-concept:C0205179, umls-concept:C0205210, umls-concept:C0205390, umls-concept:C0346647, umls-concept:C0671970, umls-concept:C0814225
pubmed:issue	22
pubmed:dateCreated	2008-8-1
pubmed:abstractText	To compare clinical benefit response (CBR) and quality of life (QOL) in patients receiving gemcitabine (Gem) plus capecitabine (Cap) versus single-agent Gem for advanced/metastatic pancreatic cancer.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Analgesics, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/capecitabine, http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	1527-7755
pubmed:author	pubmed-author:BajettaEmilioE, pubmed-author:BauerJeanJ, pubmed-author:BernhardJürgJ, pubmed-author:BodokyGyörgyG, pubmed-author:Central European Cooperative Oncology Group, pubmed-author:DietrichDanielD, pubmed-author:FigerArieA, pubmed-author:GerberDanielaD, pubmed-author:GlimeliusBengtB, pubmed-author:HerrmannRichardR, pubmed-author:KöhneClaus-HenningCH, pubmed-author:KoeberleDieterD, pubmed-author:KornekGabriela VGV, pubmed-author:MingroneWalterW, pubmed-author:PestalozziBernhard CBC, pubmed-author:RuhstallerThomasT, pubmed-author:SalettiPiercarloP, pubmed-author:SchüllerJohannesJ, pubmed-author:ScheithauerWernerW, pubmed-author:StemmerSalomon MSM, pubmed-author:TàmasKarinK
pubmed:issnType	Electronic
pubmed:day	1
pubmed:volume	26
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	3695-701
pubmed:meshHeading	pubmed-meshheading:18669454-Adenocarcinoma, pubmed-meshheading:18669454-Administration, Oral, pubmed-meshheading:18669454-Adult, pubmed-meshheading:18669454-Aged, pubmed-meshheading:18669454-Aged, 80 and over, pubmed-meshheading:18669454-Analgesics, pubmed-meshheading:18669454-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18669454-Body Weight, pubmed-meshheading:18669454-Deoxycytidine, pubmed-meshheading:18669454-Drug Administration Schedule, pubmed-meshheading:18669454-Europe, pubmed-meshheading:18669454-Female, pubmed-meshheading:18669454-Fluorouracil, pubmed-meshheading:18669454-Humans, pubmed-meshheading:18669454-Infusions, Parenteral, pubmed-meshheading:18669454-Karnofsky Performance Status, pubmed-meshheading:18669454-Male, pubmed-meshheading:18669454-Middle Aged, pubmed-meshheading:18669454-Pain, pubmed-meshheading:18669454-Pain Measurement, pubmed-meshheading:18669454-Pancreatic Neoplasms, pubmed-meshheading:18669454-Prospective Studies, pubmed-meshheading:18669454-Quality of Life, pubmed-meshheading:18669454-Time Factors, pubmed-meshheading:18669454-Treatment Failure
pubmed:year	2008
pubmed:articleTitle	Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
pubmed:affiliation	Swiss Group for Clinical Cancer Research Coordinating Center, Bern, Switzerland. juerg.bernhard@ibcsg.org
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III